Executive Vice President · ABBOTT LABORATORIES (ABT)

John Ginascol

FY2020 is the first fiscal year CompBrief holds for John Ginascol as a named executive officer of ABBOTT LABORATORIES; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$6,767,029

Salary $708,269Stock awards $1,653,678

5th of 7 named executive officers at Abbott Laboratories by FY2020 total.

7 named officers on file for ABBOTT LABORATORIES, FY2020

John Ginascol’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • ABT’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ABBOTT LABORATORIES’s whole pay program stands against its peers

  • ABBOTT LABORATORIES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 12, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get John Ginascol’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Ginascol compensation by year

ABBOTT LABORATORIES Summary Compensation Table · the one fiscal year held
In US dollars, as ABBOTT LABORATORIES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$708,269
Bonus$0
Stock awards$1,653,678
Option awards$1,653,987
Non-equity incentive$857,300
Pension and deferred compensation$1,781,066
All other$112,729
Total$6,767,029

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ABBOTT LABORATORIES DEF 14A filed March 12, 2021, accession 0001047469-21-000592, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ABBOTT LABORATORIES filed document, accession 0001047469-21-000592. Every figure is read from that document and cited to the page and table it appears in. Filed March 12, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,855$2,064,434—
RSU7,978$873,511—
RSU4,856$531,683—
RSU2,344$256,645—
Option114,940—$87.72
Option12,890—$59.94
Option25,460—$75.90
Option41,817—$76.12

Per the Outstanding Equity Awards at Fiscal Year-End table in ABBOTT LABORATORIES's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2020 proxy (filed March 12, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-03-01Sale—943$100.70118,380
2023-02-28Tax withholding—6,859$99.77119,323
2023-02-17Grant or award—14,270$0.00126,182
2023-02-17Grant or award derivative—56,275$0.0056,275

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ABBOTT LABORATORIES’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Robert FordChairman of the Board and Chief Executive Officer$20,450,586
Miles WhiteFormer Executive Chairman of the Board$19,828,384
Robert FunckExecutive Vice President, Finance$9,800,209
Hubert AllenExecutive Vice President, General Counsel and Secretary$8,478,177
John Ginascol · this pageExecutive Vice President$6,767,029
Daniel SalvadoriExecutive Vice President, Established Pharmaceuticals$5,975,739
Brian YoorExecutive Vice President, Finance and Chief Financial Officer$3,489,479

The full ABBOTT LABORATORIES compensation record

free company brief

This page is one person within ABBOTT LABORATORIES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ABBOTT LABORATORIES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ABBOTT LABORATORIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Ginascol's compensation dossier · One-time report. No refunds.